How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs
September 20, 2024 09:00 ET
|
FN Media Group LLC
PALM BEACH, Fla., Sept. 20, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Breast cancer is an illness in which the breast cells get uncontrollably large. The type of breast cancer...
Groundbreaking Market Report Forecasts Significant Growth in Cancer Immunotherapy by 2027
September 19, 2024 09:41 ET
|
Research and Markets
Dublin, Sept. 19, 2024 (GLOBE NEWSWIRE) -- The "Cancer Immunotherapy Markets. The Race for the Cures. Market Forecasts for Immuno-Oncology Therapeutics by Therapy, by Cancer and by Customer...
ImmunOs Therapeutics AG Raises $11 Million and Further Strengthens Investor Base
September 17, 2024 04:00 ET
|
AKAMPION
Existing investors and new investor Double Point Ventures join forces to support ImmunOs TherapeuticsInvestment secures funding of ongoing promising clinical trial of IOS-1002 in solid cancers ...
Immatics Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule TCER® IMA401 Targeting MAGEA4/8 at ESMO 2024 and Provides Development Update
September 16, 2024 05:25 ET
|
https://immatics.com/
TCER® IMA401 is a novel, next-generation, half-life extended bispecific T cell engager directed against an HLA-A*02-presented peptide derived from MAGEA4 and MAGEA8 with high target copy numbers on...
BioAegis Therapeutics to Present at Upcoming MedInvest Biotech & Pharma Investor Conference in NYC
September 12, 2024 16:56 ET
|
BioAegis Therapeutics
NORTH BRUNSWICK, N.J., Sept. 12, 2024 (GLOBE NEWSWIRE) -- BioAegis Therapeutics, a pioneering biotech company at the forefront of innovative therapies for inflammatory diseases, announces that its...
Le PIONeeR Project présentera pour la première fois les résultats de son étude clinique de phase Ib/IIa lors de l’ESMO 2024
September 12, 2024 04:21 ET
|
The PIONeeR Project
Le PIONeeR Project présentera pour la première fois les résultats de son étude clinique de phase Ib/IIa lors de l’ESMO 2024 Le symposium présidentiel "Eyes to the future" sera l'occasion de présenter...
The PIONeeR Project to Present Late-Breaking Results from its Phase Ib/IIa umbrella study at the ESMO Congress 2024
September 12, 2024 04:21 ET
|
The PIONeeR Project
The PIONeeR Project to Present Late-Breaking Results from its Phase Ib/IIa umbrella study at the ESMO Congress 2024 The Presidential Symposium "Eyes to the future" will feature the first-ever...
CD137 Antibodies Clinical Trials & Market Opportunity - Revolutionary CD137 Antibodies Poised to Transform Cancer Immunotherapy Landscape by 2027
September 12, 2024 04:01 ET
|
Research and Markets
Dublin, Sept. 12, 2024 (GLOBE NEWSWIRE) -- The "CD137 Antibodies Clinical Trials & Market Opportunity Insight 2027" report has been added to ResearchAndMarkets.com's offering. CD137, also...
Gastric Cancer Market Research Report 2024-2030 by Immunotherapy, Chemotherapy, Radiation Therapy, Surgery, Target Therapies, PD-1/PD-L1 Inhibitors, HER2 Antagonists VEGFR2 Antagonists
September 11, 2024 11:03 ET
|
Research and Markets
Dublin, Sept. 11, 2024 (GLOBE NEWSWIRE) -- The "Global Gastric Cancer Market (2024 Edition): Analysis By Indication (Gastric Cancer/Gastroesophageal Junction Cancer, Gastrointestinal Stromal...
Testicular Cancer Drugs Market Forecast Report 2024-2030 - Focus on Reducing Treatment Toxicity Enhances Demand for Novel Testicular Cancer Drugs
September 09, 2024 11:20 ET
|
Research and Markets
Dublin, Sept. 09, 2024 (GLOBE NEWSWIRE) -- The "Testicular Cancer Drugs - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Testicular...